Introduction
Ovarian cancer has the highest mortality rate among gynecological malignancies in industrialized countries. With current protocols, a 70%-80% response to first-line chemotherapeutics can be achieved; however, most cases relapse and eventually succumb after metastasis. 1 Successful ovarian cancer therapy depends greatly upon the effectiveness of cytotoxic anticancer drugs. Resistance to chemotherapeutics is submit your manuscript | www.dovepress.com
Dovepress

8902
Zhang et al associated with ovarian cancer relapse. However, the related mechanisms remain largely undefined.
Genistein (4′,5,7-trihydroxyisoflavone) naturally occurs in fruits, nuts, and soybeans and potently inhibits cancers, including breast, prostate, liver, ovarian, bladder, gastric, and brain cancers as well as neuroblastomas and chronic lymphocytic leukemia. 2 Genistein acts as a chemotherapeutic agent against different types of cancer, by inhibiting inflammation, promoting apoptosis, and regulating steroid hormone receptors and metabolic pathways. 3, 4 The antitumor properties of genistein have been intensively described in many cancers, but related studies evaluating ovarian cancer are scarce.
We have previously confirmed that a genistein analog can suppress PI3K/AKT signaling 5 and the FoxO signaling pathway. [6] [7] [8] With advances in genomics, network analysis could help dissect multiple human diseases. In this study, DrugBank database 9 was used to broadly assess genistein and drug-target data. Then, the prediction of drug-target interactions was performed with STRING database. 10 Protein-protein interaction (PPI) network modules with significance were assessed using the Molecular Complex Detection (MCODE) software. 11 Then, associated genes were obtained for further exploration of genomic changes with the cBio Cancer Genomics Portal (cBioPortal) database. 12, 13 The Kaplan-Meier method 14 was employed for survival assessment. Our findings demonstrated that drug-target-disease network (DTDN) analysis is valuable in exploring the mechanisms associated with genistein's effects on ovarian cancer, broadening the perspective of targeted therapies.
Materials and methods
Drug-target search
The DrugBank database is a comprehensive, freely accessible, online database containing information on drugs and drug targets. As DrugBank is both a bioinformatics and a cheminformatics resource, it combines detailed drug (ie, chemical, pharmacological, and pharmaceutical) data with comprehensive drug target (ie, sequence, structure, and pathway) information.
9 DrugBank (https://www.drugbank.ca/) was employed to identify interactions between genistein and its target molecules. Genistein was searched as a keyword under drug classification entry.
PPi network generation and module assessment
STRING is a database of known and predicted PPIs. 10 The STRING resource is available online at http://string-db.org/. Prediction of drug interactions with targets (including secondary targets) was performed with STRING. Interaction pairs with overall score above 0.9 were recorded for PPI network generation based on the Cytoscape software (http:// www.cytoscape.org/). 15 Genes with intense interconnections were grouped into a module. Then, PPI network modules with significance were assessed using MCODE (http://baderlab. org/Software/MCODE). 12, 13 It was employed to assess the connectivity of genistein-related genes in all ovarian cancer reports. Using the portal search function, genistein-related genes in ovarian cancer publications were evaluated for genomic alterations across a set of patients, performing network analysis and identifying trends, eg, mutual exclusivity or co-occurrence between gene pairs of the same gene set.
analysis of genistein-associated genes and ovarian cancer survival
The Kaplan-Meier method 14 (http://kmplot.com/) was employed to evaluate the effects of 54,675 genes on survival in 10,461 cancer cases, including 1,816 ovarian cancer cases with mean follow-up periods of 69, 40, 49, and 33 months. Altered genes were then assessed by the Kaplan-Meier method for evaluating ovarian cancer survival according to gene expression.
Results
characterization of genistein using DrugBank
DrugBank resources (version 5.1.0; released April 2, 2018) were used to identify the bioactivities of genistein and 
PPIs identified with the MCODE analysis tool
Proteins encoded by the 13 target genes associated with genistein were considered primary protein targets. A total of 372 target-protein interactions were detected using STRING and further analyzed with the MCODE analysis tool to determine critical genes. The top 72 genes are shown in Figure 1 .
Pathway enrichment of hub genes using Kegg analysis
Hub genes were found in 80 molecular pathways in KEGG (WebGestalt) enrichment. 16, 17 The first 10 KEGG hits included pathways in cancer (48 genes), PI3K/AKT signaling pathway (36 genes), hepatitis B and prostate cancer (30 genes), Kaposi's sarcoma-associated herpesvirus infection (28 genes), HTLV-I infection (27 genes), breast cancer, human papillomavirus infection and breast cancer (26 genes), and FoxO signaling pathway and proteoglycans in cancer (25 genes). The obtained KEGG enrichment pathways reflected functional features of genistein gene sets, and further assessment was performed. We have previously shown that a genistein analog can suppress PI3K/AKT signaling 5 as well as the FoxO signaling pathway. To identify disease targets for ovarian cancer, we searched "ovarian cancer" in CTD (revision 15462). 18 A total of 123 genes with curated associations to the disease with the marker "T" or "M" only were recorded. "M" means a gene that may be a biomarker of a disease or play a role in the etiology of a disease. "T" means a gene that is or may be a therapeutic target in the treatment of a disease. Seven overlapping genes (CDKN1B, PTEN, EGFR, MAPK1, MAPK3, PIK3CA, and AKT1) resulted from the intersections of the three pathways alongside the 123 abovementioned genes were visualized using Venn diagrams (Figure 2 ). Further analysis of the seven selected overlapping genes was performed.
genomic alterations of genisteinassociated genes in ovarian cancer
Only two ovarian carcinoma studies were included in cBioPortal (Version 1.13.1). The seven genes (CDKN1B, PTEN, EGFR, MAPK1, MAPK3, PIK3CA, and AKT1) associated with the ovarian cancer pathway were searched, and two reports were involved. The results showed that 107 (33%) of the 327 sequenced cases had alterations in one or more of these genes; alteration frequencies are shown in Figure 3 . PTEN (8%) alterations mostly included deep deletions. The seven genes (CDKN1B, PTEN, EGFR, MAPK1, MAPK3, PIK3CA, and AKT1) had 16 gene pairs showing mutually exclusive alterations (with no statistical significance), while five had concurrent alterations (with no statistical significance).
Next, cBioPortal was employed for interactive analysis and to generate networks of genes showing alterations in cancer; the neighbors of the abovementioned seven genes are shown in Figure 4 . Only neighbors with high alteration frequencies are shown in Figure 4 . The seven genes were found to be related to TP53, and a filter of $64.1% alteration frequency was used. Meanwhile, nine genes, including TP53 and MYC, were identified with a filter of $32.6% alteration 
genistein-associated genes and survival in ovarian cancer
The seven selected genes (CDKN1B, PTEN, EGFR, MAPK1, MAPK3, PIK3CA, and AKT1) identified were employed to perform survival analysis with clinical profiles in ovarian cancer. As shown in Figure 5 , elevated CDKN1B amounts showed correlation with overall survival (log-rank P=0.021) according to Kaplan-Meier analysis, with cases grouped by mean mRNA levels.
Discussion
A PubMed search with "genistein and cancer" returned over 2,963 publications where Akiyama et al 19 reported that genistein inhibits the EGF receptor. Multiple biologically relevant effects have been described for genistein. For example, genistein is known to inhibit Glut receptors, 20 which is overexpressed in cancer cells, which may be the probable reason for its anticancer activity. 21 However, the mechanisms by which genistein exerts these beneficial effects are not fully understood. Therefore, novel methods or platforms that could 
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DTDn analysis of genistein in ovarian cancer bridge genistein to its targets are required for the evaluation of biological effect.
The present study used the functional/activity network (FAN) analysis 22 and performed functional network analysis with multiple web-based tools. Using a system biochemistry approach integrating DrugBank and STRING and WebGestalt, associations of ovarian cancer and molecules with drug targets were globally detected. A total of 13 primary and 372 secondary target genes/proteins (Supplementary materials) were obtained. The top 72 genes in MCODE and 10 enriched KEGG pathways related to genes altered by genistein are summarized in Table 2 . To obtain disease targets for ovarian cancer, we searched "ovarian cancer" in CTD and identified 123 genes showing associations only with the marker "T" or "M" only; in addition, seven overlapping genes (CDKN1B, PTEN, EGFR, MAPK1, MAPK3, PIK3CA, and AKT1) were found in the intersection of the three pathways and the 123 genes in CTD. 
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DTDn analysis of genistein in ovarian cancer We previously demonstrated that a genistein analog significantly suppresses tumor stemness and promotes ovarian cancer cell apoptosis through FOXM1 downregulation and FOXO3a induction, [6] [7] [8] suppressing PI3K/AKT signaling. 5 Meanwhile, Li et al 23 identified the highly mutated super enhancer CDKN1B with concordant gene expression changes in their target genes and prognostic significance for ovarian cancer. In this study, high mRNA CDKN1B amounts showed correlation with overall survival in ovarian cancer. Guo et al 24 reported that G6PC silencing induces cell cycle-associated proteins and restores CDKN1B expression. Peng et al 25 described the small natural compound goniothalamin (GTN) as a CKI inducer. GTN stabilizes CDKN1B protein expression by degrading its specific E3 ubiquitin ligase (S-phase kinase-associated protein 2). Therefore, the mechanisms between genistein and CDKN1B protein expression should be studied in in vitro experiments.
Conclusion
We reported in this study a new method, DTDN analysis, to investigate the underlying mechanisms of genistein action and broaden the perspective of targeted therapies in ovarian carcinoma. We employed DTDN method to analyze DrugBank, STRING, and WebGestalt databases and found that MAPK, PIK3CA, and AKT1 are associated with ovarian cancer, which agrees with our experimental study result reported. Furthermore, using the reported method, we observed a correlation between high expression of mRNA CDKN1B and low overall survival rate in ovarian cancer, indicating a new gene target worthy of further in vitro experimental study. Our work showed that DTDN analysis could facilitate the interpretation of the disease mechanisms of ovarian cancer and the identification of new targets, hence could help accelerate the investigation of genistein's anticancer effects by screening potential gene targets to be studied in in vitro experiments.
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